New combo tackles tough pancreatic cancer
NCT ID NCT05052723
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested two drugs, cabozantinib and pembrolizumab, in 21 people with metastatic pancreatic cancer that had worsened after standard treatment. The goal was to see if the combination could slow cancer growth. The study is complete, and results may help guide future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cabozantinib and pembrolizumab
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced pancreatic cancer that has not responded to standard therapies.
- What could go wrong
- This is a small, early-phase trial with only 21 participants, so results may not apply to everyone. The drugs can cause side effects, and the cancer may still progress.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Kentucky Markey Cancer Center
Lexington, Kentucky, 40536, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug immune attack shrink Hard-to-Treat pancreatic tumors?
- Could a vaccine help fight Hard-to-Treat cancers?
- Blood and gut clues may flag pancreatic cancer risk early
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- MRI might reveal hidden pancreatic risks in obesity
- Can a new PET tracer light up hidden cancers?